How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Hotels ranked on industry awards, guest reviews and hotel class ratings Unbiased content created by U.S. News editors Photo tours of select hotels by local experts Navigate forward to interact with ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Kellogg is rolling out Cocoa Loops nationwide, with full availability by January. The cereal is ...

Neal has more than 20 years of experience in financial and business journalism covering retail investing, airlines, pharmaceuticals, healthcare, sustainability, technology, and retail. He has worked ...

Ashlyn is one of Forbes Home's in-house writers and a former civil engineer-turned content writer with over six years experience. Until recently, Ashlyn focused on creating content for Forbes Home as ...